Abbott wins CE Mark for Alinity h-series hematology system

Abbott (NYSE:ABT) said today it won CE Mark approval in the European Union for its Alinity h-series integrated hematology testing system and that it launched the device in the associated regions. The newly cleared system features integration of the Alinity hq system with the Alinity hs slide marker and stainer module. The company touts the system as operating 20% faster than other integrated hematology systems. “Today’s hematology laboratories are challenged to perform more tests while reducing errors and operating costs. With built-in simplicity designed specifically for hematology testing, the Alinity h-series is smaller, faster, and more automated than current systems, incorporating advanced features that allow health care professionals to spend less time managing the process of producing results and more time helping patients,” diagnostics prodcuts exec VP Brian Blaser said in a prepared statement. Abbott said the Alinity h-series features enhanced workflow to integrate workstations into a single platform, custom scaling and system module integration to meet specific needs and reduced wait time via continuous access. “The Alinity h-series is designed around feedback and insights specifically gathered from hematology customers. System uptime and results accuracy are two examples of high priority needs for high-volume laboratories. With this in mind, a rigorous reliability growth program was executed for the Alinity h-series systems involving milli...
Source: Mass Device - Category: Medical Devices Authors: Tags: Blood Management Diagnostics Regulatory/Compliance Abbott Source Type: news